A list of upcoming conferences, workshops and educational events, with dates, locations and web links for more information and registration.
November
Inhaled Drug Delivery. November 1-2, 2018. Con-
ducted by Management Forum. https://manage
m e n t - f o r u m . c o . u k / p r o d u c t / d e t a i l s / 1 7 1 4 /
inhaled-drug-delivery
PharmSci360. November 4-7, 2018 in Washington,
DC. Conducted by the American Association of Phar-
maceutical Scientists. www.aaps.org/annual-meet
ing-and-conferences/annual-meeting
RDD
®
Asia 2018. November 14-16, 2018 in Kerala,
India. Conducted by RDD Online and Aptar Pharma.
www.rddonline.com/rdd/rdd.php?id=16
December
Drug Delivery to the Lungs 2018. December 12-14,
2018 in Edinburgh, UK. Conducted by the Aerosol
Society. https://aerosol-soc.com/events/ddl2018
CALENDAR
To be featured at AAPS PharmSci360 and DDL2018
If you are attending AAPS PharmSci 360 or DDL2018, please
visit Inhalation's advertisers. See the following link for
information on the products and services they will be
exhibiting: https://www.inhalationmag.com/digital_inh/
INH_upcoming/INH_new_upcoming.html
To be featured at AAPS PharmSci360 and DDL2018
Development and manufacturing for
novel respiratory products
Recipharm and Sanofi
have completed the trans-
fer of Sanofi's Holmes
Chapel, UK site to leading
pharmaceutical CDMO,
Recipharm. e new facil-
ity, which includes devel-
opment and manufactur-
ing capabilities for novel
respiratory products, com-
plements the inhalation
development expertise
o ered by the Recipharm
team in Research Triangle
Park, North Carolina,
US. e prime technologies manufactured at the facility
include metered dose inhalers and nasal sprays. It also
houses several development suites speci cally for dry
powder and other inhalation technologies.
Recipharm
Sweden: + 46 8 602 52 00
www.recipharm.com
Product development and compliant
manufacture
Hovione o ers development and compliant manufac-
ture of innovative new drugs and niche generic active
pharmaceutical ingredient (API) products. Hovione also
supports highly potent compounds and o ers propri-
etary product development and licensing opportunities
for drug products. e company undertakes formulation
development and clinical supply of nal dosage forms to
Phase II. With strong expertise in pulmonary delivery,
Hovione also o ers APIs for inhala tion, DPI devices and
particle engineer ing services.
Hovione
Portugal: +351 21 982 9000
www.hovione.com
Inhalation OCTOBER 2018 25
SUBSCRIBE TODAY
www.inhalationmag.com